News
Brain and mental health innovation shortlist revealed
Three innovative companies have been shortlisted for a Femtech World Award.
The Brain and Mental Health Innovation award honours a breakthrough innovation that has made a profound impact on the understanding, treatment, or management of brain and mental health conditions.
This award recognises an innovation that has advanced the field by improving patient outcomes, increasing accessibility to care or offering new insights into mental wellness.
The award is sponsored by Women in Cloud – a community-led economic development organisation taking action to generate $1B in net new global economic access for women entrepreneurs by 2030 through partnerships with corporations, community leaders, and policy makers.
The Women in Cloud Initiative is led in collaboration with industry and community partners such as Microsoft, M12 – Microsoft’s Venture Capital Fund, Accenture, Hitachi Solutions, Insight, Boeing, Meylah, and more.
A winner from the shortlist will be chosen by the sponsor and announced at a virtual ceremony on May 28.
Congratulations to the shortlisted organisations and thank you to everyone who entered.
Brain and Mental Health Innovation Award Shortlist

Women’s mental health is deeply connected to hormonal fluctuations, yet traditional testing is slow, expensive, and impractical for continuous monitoring.
Eli Health’s Hormometer provides real-time, at-home hormone tracking, helping women understand how cortisol, progesterone, estradiol, and testosterone impact stress, mood, and cognition.
Cortisol and progesterone testing launch in Q1 2025, with estradiol and testosterone in development, offering a comprehensive view of hormonal brain health.
At around $8 per test, Eli makes mental health support more accessible and data-driven. No more guesswork—women can finally track, understand, and take control of their mental well-being.



One in eight couples struggle to conceive, and 42 per cent of Americans have either sought fertility treatment themselves or know someone who has. As awareness around fertility challenges becomes more widespread, many are left to navigate an isolating and emotional journey with minimal resources.
In response to growing demand for fertility-centered mental health resources, Headspace partnered with fertility experts from Spring Fertility to create “Support For Your Fertility Journey.”
The content collection features guided meditations and mindfulness exercises, audio conversations, and a docu-style video series.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







